Lv2
120 积分 2026-04-17 加入
Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma
2天前
已完结
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
2天前
已完结
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
6天前
已完结
伴t（4;14）初诊多发性骨髓瘤的临床特征及预后分析
19天前
已完结
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
1个月前
已完结
CAR-T cell therapy for patients with extramedullary multiple myeloma：Opportunities and challenges
1个月前
已完结
Challenges facing CAR T-cell immunotherapy in multiple myeloma
2个月前
已完结
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
2个月前
已完结
Late and Durable Minimal Residual Disease Response Predicts Favorable Outcomes in Newly Diagnosed Multiple Myeloma
2个月前
已完结
Human herpesvirus 6 (HHV-6) encephalitis secondary to chimeric antigen receptor (CAR)-T cell therapy
3个月前
已完结
皖公网安备34019202002308
